Dr. Peter Marks is being forced to resign from the FDA because the Trump administration does not want someone who is ...

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...

Kennedy, a well-known vaccine skeptic, last week announced plans to reshape federal public health agencies, including cutting ...

US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.

While it’s not unusual for certain positions to turn over with a new administration, the number of senior-level FDA staffers ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%. 4/11 ...

"Just where is that extensive 5000 word longform apology from Adam Cifu over at Sensible Medicine, begging forgiveness for ...

On the precipice of FDA approval, Novavax's Covid vaccine is now in limbo while a decision to approve or reject it is held up ...

Ousted FDA biologics and vaccine chief Peter Marks was asked to provide non-existent data on the risk from measles vaccines, ...